Medikine Appoints Roland Buelow, Ph.D., to Board of Directors
06 Dec 2022 //
BUSINESSWIRE
Medikine Presents Preliminary Results of Single-DosePh1 Healthy Subject MDK-703
10 Nov 2022 //
BUSINESSWIRE
Medikine to Present Phase 1 Trial Results for MDK-703
05 Oct 2022 //
BUSINESSWIRE
Medikine Initiates First Trial of its Lead Program, an Interleukin-7 Mimetic
19 Jul 2022 //
BUSINESSWIRE
Medikine to Highlight Preclinical Data on its Lead Program MDK-703 at AACR
06 Apr 2022 //
BUSINESSWIRE

Market Place
Sourcing Support